BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 32699115)

  • 1. Gene of the month:
    Pinto K; Chetty R
    J Clin Pathol; 2020 Sep; 73(9):527-530. PubMed ID: 32699115
    [TBL] [Abstract][Full Text] [Related]  

  • 2. GLIS Rearrangement is a Genomic Hallmark of Hyalinizing Trabecular Tumor of the Thyroid Gland.
    Nikiforova MN; Nikitski AV; Panebianco F; Kaya C; Yip L; Williams M; Chiosea SI; Seethala RR; Roy S; Condello V; Santana-Santos L; Wald AI; Carty SE; Ferris RL; El-Naggar AK; Nikiforov YE
    Thyroid; 2019 Feb; 29(2):161-173. PubMed ID: 30648929
    [TBL] [Abstract][Full Text] [Related]  

  • 3. GLIS rearrangements in thyroid nodules: A key to preoperative diagnosis of hyalinizing trabecular tumor.
    Nikiforova MN; Nikiforov YE; Ohori NP
    Cancer Cytopathol; 2019 Sep; 127(9):560-566. PubMed ID: 31373774
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Emerging Roles of GLI-Similar Krüppel-like Zinc Finger Transcription Factors in Leukemia and Other Cancers.
    Jetten AM
    Trends Cancer; 2019 Sep; 5(9):547-557. PubMed ID: 31474360
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gli-similar (Glis) Krüppel-like zinc finger proteins: insights into their physiological functions and critical roles in neonatal diabetes and cystic renal disease.
    Kang HS; ZeRuth G; Lichti-Kaiser K; Vasanth S; Yin Z; Kim YS; Jetten AM
    Histol Histopathol; 2010 Nov; 25(11):1481-96. PubMed ID: 20865670
    [TBL] [Abstract][Full Text] [Related]  

  • 6. GLIS1-3 transcription factors: critical roles in the regulation of multiple physiological processes and diseases.
    Jetten AM
    Cell Mol Life Sci; 2018 Oct; 75(19):3473-3494. PubMed ID: 29779043
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PAX8-GLIS3 gene fusion is a pathognomonic genetic alteration of hyalinizing trabecular tumors of the thyroid.
    Marchiò C; Da Cruz Paula A; Gularte-Merida R; Basili T; Brandes A; da Silva EM; Silveira C; Ferrando L; Metovic J; Maletta F; Annaratone L; Pareja F; Rubin BP; Hoschar AP; De Rosa G; La Rosa S; Bongiovanni M; Purgina B; Piana S; Volante M; Weigelt B; Reis-Filho JS; Papotti M
    Mod Pathol; 2019 Dec; 32(12):1734-1743. PubMed ID: 31273314
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gli-similar proteins: their mechanisms of action, physiological functions, and roles in disease.
    Lichti-Kaiser K; ZeRuth G; Kang HS; Vasanth S; Jetten AM
    Vitam Horm; 2012; 88():141-71. PubMed ID: 22391303
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oncogenic properties and signaling basis of the PAX8-GLIS3 fusion gene.
    Basili T; Dopeso H; Kim SH; Ferrando L; Pareja F; Da Cruz Paula A; da Silva EM; Stylianou A; Maroldi A; Marchiò C; Rubin BP; Papotti M; Weigelt B; Moreira Ferreira CG; Lapa E Silva JR; Reis-Filho JS
    Int J Cancer; 2020 Oct; 147(8):2253-2264. PubMed ID: 32383186
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of nuclear localization, DNA binding, and transactivating mechanisms of Kruppel-like zinc finger protein Gli-similar 2 (Glis2).
    Vasanth S; ZeRuth G; Kang HS; Jetten AM
    J Biol Chem; 2011 Feb; 286(6):4749-59. PubMed ID: 21127075
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Krüppel-like zinc finger protein Gli-similar 2 (Glis2) represses transcription through interaction with C-terminal binding protein 1 (CtBP1).
    Kim SC; Kim YS; Jetten AM
    Nucleic Acids Res; 2005; 33(21):6805-15. PubMed ID: 16326862
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A thyroid-specific far-upstream enhancer in the human sodium/iodide symporter gene requires Pax-8 binding and cyclic adenosine 3',5'-monophosphate response element-like sequence binding proteins for full activity and is differentially regulated in normal and thyroid cancer cells.
    Taki K; Kogai T; Kanamoto Y; Hershman JM; Brent GA
    Mol Endocrinol; 2002 Oct; 16(10):2266-82. PubMed ID: 12351692
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Thyroid defects due to Pax8 gene mutations.
    Damante G
    Eur J Endocrinol; 1998 Dec; 139(6):563-6. PubMed ID: 9916856
    [No Abstract]   [Full Text] [Related]  

  • 14. Decreased expression of thyrotropin receptor gene suggests a high-risk subgroup for oncocytic adenoma.
    Mirebeau-Prunier D; Guyétant S; Rodien P; Franc B; Baris O; Rohmer V; Reynier P; Tourmen Y; Malthièry Y; Savagner F
    Eur J Endocrinol; 2004 Mar; 150(3):269-76. PubMed ID: 15012610
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PAX8, TITF1, and FOXE1 gene expression patterns during human development: new insights into human thyroid development and thyroid dysgenesis-associated malformations.
    Trueba SS; Augé J; Mattei G; Etchevers H; Martinovic J; Czernichow P; Vekemans M; Polak M; Attié-Bitach T
    J Clin Endocrinol Metab; 2005 Jan; 90(1):455-62. PubMed ID: 15494458
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The expression of PAX8-PPARgamma rearrangements is not specific to follicular thyroid carcinoma.
    Nakabashi CC; Guimarães GS; Michaluart P; Ward LS; Cerutti JM; Maciel RM
    Clin Endocrinol (Oxf); 2004 Aug; 61(2):280-2. PubMed ID: 15272927
    [No Abstract]   [Full Text] [Related]  

  • 17. Development of the thyroid gland: lessons from congenitally hypothyroid mice and men.
    Van Vliet G
    Clin Genet; 2003 Jun; 63(6):445-55. PubMed ID: 12786749
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MYC promotes the development of papillary thyroid carcinoma by inhibiting the expression of lncRNA PAX8‑AS1:28.
    Zhang Y; Li F; Chen J
    Oncol Rep; 2019 Apr; 41(4):2511-2517. PubMed ID: 30720110
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Determination of functional domains of the human transcription factor PAX8 responsible for its nuclear localization and transactivating potential.
    Poleev A; Okladnova O; Musti AM; Schneider S; Royer-Pokora B; Plachov D
    Eur J Biochem; 1997 Aug; 247(3):860-9. PubMed ID: 9288908
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Thyroid transcription factor 1 rescues PAX8/p300 synergism impaired by a natural PAX8 paired domain mutation with dominant negative activity.
    Grasberger H; Ringkananont U; Lefrancois P; Abramowicz M; Vassart G; Refetoff S
    Mol Endocrinol; 2005 Jul; 19(7):1779-91. PubMed ID: 15718293
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.